Project Description

The MABTOX consortium has complementary proprietary technologies and proposes to leverage this expertise and know-how for defining novel processes of enzymatically conjugating small molecule toxins to antibodies that allow full control about toxin coupling site and ratio.

Abstract

Therapeutic antibodies have transformed cancer therapy during the last decade, due to their high selectivity of targeting cancer cells in comparison to standard small molecule chemotherapy. Most recently, the coupling of cellular toxins to therapeutic antibodies has demonstrated an even greater efficacy in the therapy of cancer and the first, highly potent antibody drug conjugate (ADC), Adcetris®, was FDA approved in August 2011. All ADCs currently in clinical development are generated by chemical conjugation of small molecule toxins to antibodies. This is an inefficient process, as site and ratio of toxin coupling cannot be controlled.
The consortium has complementary proprietary technologies and proposes to leverage this complementary expertise and know-how for defining novel processes of enzymatically conjugating small molecule toxins to antibodies that allow full control about toxin coupling site and ratio. Due to the high selectivity of enzymatic conjugation and physiologic conjugation conditions, it is expected that more homogeneous ADCs are generated with better CMC properties, higher potency, and at lower cost-of-goods in manufacturing.

Project Details

Coordinator: 
NBE-Therapeutics GmbH
Partners: 
accelopment AG, CH (service provider)
ZIP Solutions S.L., ES
Tube Pharmaceuticals GmbH, AT
evitria AG, CH
Protagen Protein Services GmbH, DE
Oncotest GmbH Prof. Dr. H. H. Fiebig, DE
JPT Peptide Technologies GmbH, DE
Biomedal SL, ES
TBD-Biodiscovery OU, EE
InnoTune BVBA, BE
Contact: 
Dr Ulf Grawunder
Duration: 
01.10.2013 - 31.12.2015
Budget: 
1.1 million euro
Our Services: 
Project Management
Funding Programme: 
  • FP7-SME
Area: 
Biotechnology